Welcome to CDC Stacks | Survey of the Anti-Factor IX Immunoglobulin Profiles in Patients With Hemophilia B Using a Fluorescence-Based Immunoassay - 42303 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Survey of the Anti-Factor IX Immunoglobulin Profiles in Patients With Hemophilia B Using a Fluorescence-Based Immunoassay
  • Published Date:
    Sep 17 2016
  • Source:
    J Thromb Haemost. 14(10):1931-1940.


Public Access Version Available on: October 01, 2017 information icon
Please check back on the date listed above.
Details:
  • Pubmed ID:
    27501440
  • Pubmed Central ID:
    PMC5083216
  • Funding:
    CC999999/Intramural CDC HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Background

    Hemophilia B (HB) is an inherited bleeding disorder caused by the absence or dysfunction of coagulation factor IX (FIX). A subset of patients who have HB develop neutralizing alloantibodies (inhibitors) against FIX following infusion therapy. HB prevalence and the proportion of patients who develop inhibitors are much lower than that of hemophilia A (HA), which makes studies of inhibitors in patients with HB challenging due to the limited availability of samples. As a result, there is a knowledge gap regarding HB inhibitors.

    Objective

    Evaluate the largest group of inhibitor positive HB patients studied to date to assess the relationship between anti-FIX antibody profiles and inhibitor formation.

    Methods

    A fluorescence immunoassay (FLI) was used to detect anti-FIX antibodies in plasma samples from 37 patients with HB.

    Results

    Assessments of antibody profiles showed that anti-FIX IgG1-4, IgA, and IgE were detected significantly more often in patients with a positive Nijmegen-Bethesda Assay (NBA). All NBA-positive samples were positive for IgG4. Anti-FIX IgG4 demonstrated a strong correlation with the NBA, while correlations were significant, yet more moderate, for anti-FIX IgG1-2 and IgA.

    Conclusions

    The anti-FIX antibody profile in HB patients who develop inhibitors is diverse and correlates well with the NBA across immunoglobulin (sub)class, and anti-FIX IgG4 is particularly relevant to functional inhibition. The anti-FIX FLI may serve as a useful tool to confirm the presence of antibodies in patients who have low positive NBA results and to more clearly define, predict, and treat alloantibody formation against FIX.

  • Supporting Files:
    No Additional Files